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Reactivity of factor IXawith basic pancreatic trypsin inhibitor
is enhanced by lowmolecular weight heparin (enoxaparin). Pre-
vious studies by us have suggested that this effect involves allo-
steric modulation of factor IXa. We examined the reactivity of
factor IXa with several isolated Kunitz-type inhibitor domains:
basic pancreatic trypsin inhibitor, the Kunitz inhibitor domain
of proteaseNexin-2, and the first two inhibitor domains of tissue
factor pathway inhibitor. We find that enhancement of factor
IXa reactivity by enoxaparin is greatest for basic pancreatic tryp-
sin inhibitor (>10-fold), followed by the second tissue factor
pathway inhibitor domain (1.7-fold) and the Kunitz inhibitor
domain of protease Nexin-2 (1.4-fold). Modeling studies of fac-
tor IXawith basic pancreatic trypsin inhibitor suggest that bind-
ing of this inhibitor is sterically hinderedby the 99-loopof factor
IXa, specifically residue Lys98. Slow-binding kinetic studies sup-
port the formation of a weak initial enzyme-inhibitor complex
between factor IXa and basic pancreatic trypsin inhibitor that is
facilitated by enoxaparin binding. Mutation of Lys98 to Ala in
factor IXa results in enhanced reactivity with all inhibitors
examined,whereas almost completely abrogating the enhancing
effects of enoxaparin. The results implicate Lys98 and the
99-loop of factor IXa in defining enzyme inhibitor specificity.
More importantly, these results demonstrate the ability of factor
IXa to be allostericallymodulated by occupation of the heparin-
binding exosite.
Factor IXa (fIXa)2 is a vitamin K-dependent blood coagula-
tion factor that is essential for the amplification or “consolida-
tion” phase of blood coagulation (1, 2). As with other blood
coagulation factors (namely factors VIIa, Xa, and thrombin)
fIXa is amember of the serine protease family and shares a high
degree of homology with trypsin. Despite this homology, the
blood coagulation enzymes differ drastically from trypsin in
that their activities are profoundly modulated by the binding of
various protein and non-protein cofactors. In the case of fIXa,
the ability of activated factor VIII (fVIIIa), anionic phospho-
lipid, and ionic calcium to enhance the procoagulant activity of
fIXa is well documented (3–6); resulting in a 109-fold increase
in activity of fIXa. Themolecular details of this conversion have
not been defined in total and are the subject of intense investi-
gation by numerous groups.
Themajor inhibitor of fIXa in plasma is antithrombin, whose
reactivity with fIXa essentially requires heparin (7–9). Heparin
is known to bind to antithrombin and sterically alter its confor-
mation to allow this serpin to react with its target (10–13).
Heparin also binds to fIXa (14) allowing long chains of heparin
to additionally catalyze the interaction of fIXa with antithrom-
bin via the formation of bridged complexes where heparin acts
as a “template.” Recently, we have shown that low molecular
weight heparin binding to fIXa enhances reactivity of fIXa with
the Kunitz-type inhibitor BPTI (15), suggesting that oligosac-
charide binding can also allosterically modulate the fIXa active
site region. In this study we examine in greater detail the ability
of heparin to modulate fIXa reactivity toward several isolated
Kunitz-type inhibitor domains. We show that the modulatory
effect of heparin can be completely abrogated by mutating a
single amino acid residue in the 99-loop region of the extended
fIXa active site cleft outside of the heparin binding exosite.
EXPERIMENTAL PROCEDURES
Materials—Factor IXa, factor VIIa, factor XIa, and the fac-
tor X activator from Russell’s Viper venom were purchased
from Hematologic Technologies Inc. (Essex Junction, VT).
Recombinant soluble tissue factor (the extracellular domain of
tissue factor) was expressed and purified from bacteria as pre-
viously described (16). Factor Xa was prepared from plasma-
derived factor X as previously described (17). Enoxaparin
(Lovenox) was purchased from Aventis Pharmaceuticals
(Bridgewater, NJ). Purified heparin-derived oligosaccharides of
6, 10, 14, and 18 saccharide units (H6, H10, H14, andH18) were
prepared and characterized essentially as described (18–20)
and were a generous gift of Dr. Steven T. Olson, University of
Illinois, Chicago, IL. Bovine serum albumin (Fraction V, fatty
acid free) was from Calbiochem (La Jolla, CA), and ethylene
glycol was from Fisher Scientific. The chromogenic substrate
CBS 31.39 (CH3SO2-D-LGR-pNA) was purchased from Diag-
nostica Stago (Parsippany, NJ). All other reagents were of the
highest quality available.
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Construction and Expression of Recombinant Inhibitors—
Appropriate expression clones encoded for: BPTI (59 amino
acids) (21, 22), PN2-KPI (61 amino acids corresponding to res-
idues 285–344 of Protease Nexin-2) (23), TFPI-K1 (58 amino
acids corresponding to residues 50–107 of TFPI) (24), and
TFPI-K2 (59 amino acids corresponding to residues 121–178 of
TFPI) (24). Each construct was directionally cloned into
pET11a (Novagen) and verified by sequencing. Inhibitors were
expressed as inclusion bodies in Escherichia coli strain
BL21(DE3). Transformed bacterial cells were first grown to log
phase at 37 °C in TB media containing 50 g/ml carbenicillin.
Protein expressionwas induced by addition of isopropyl 1-thio-
-D-galactopyranoside to 0.5 mM (0.1mM for TFPI-K1) and the
cells were allowed to continue growing for 4 h at 37 °C.
Inclusion bodies were isolated essentially as described (25)
and solubilized with 6 M guanidine HCl containing 20 mM di-
thiothreitol, 50mMTris-HCl, pH8.0, and 1mMEDTA to obtain
a total protein concentration of roughly 20mg/ml. The solution
was then clarified by centrifugation (16,000 g for 30min) and
oxidative refolding (26) of each protein preparation was per-
formed by rapid dilution into 20 volumes of buffer containing
50 mM Tris-HCl, pH 8.0, 1 M guanidine HCl, 1 mM EDTA, 2.5
mM oxidized glutathione (Sigma), and 1mM dithiothreitol. The
diluted protein solutionwas incubated at room temperature for
6 h with slow stirring for completion of protein refolding fol-
lowed by exhaustive dialysis into an appropriate buffer for ion-
exchange chromatography.
Construction and Expression of Wild-type and Mutant fIX—
The coding sequence for wild-type fIX in pBR322 (27) was a
generous gift of Dr. Earl Davie (University ofWashington). The
fIX coding sequence was removed into the mammalian expres-
sion vector pcDNA3 (Invitrogen) and sequenced to verify the
correct orientation. This construct (pFN04) was used for
expression of wild-type fIX as well as PCR-based mutagenesis
(28) to generate fIXK98A essentially as previously described for
constructing fVII mutants (29). Expression constructs were
transfected into human 293 cells using Lipofectin (Invitrogen)
and high expressing clones isolated by limiting dilution.
Protein Purifications—Purification of refolded BPTI was
accomplished by ion-exchange chromatography usingMono-S
HR 5/5 (Amersham Biosciences) in 20 mM Tris-HCl, pH 8.0.
The column was developed with a 0–1 M NaCl gradient and
BPTI eluted as a single peak at roughly 0.43 M NaCl. The spe-
cific activity of recombinant BPTI preparations was equivalent
to or better than that of commercial preparations of aprotinin
(not shown). Purification of refolded PN2-KPI and TFPI-K2
was accomplished by ion-exchange chromatography using
Mono-Q HR 5/5 (Amersham Biosciences) in 20 mM MES, pH
6.0. In both cases the column was developed with a 0–0.5 M
NaCl gradient. PN2-KPI eluted at roughly 90 mM NaCl and
TFPI-K2 eluted at roughly 50mMNaCl. Purification of refolded
TFPI-K1 was accomplished by affinity chromatography over a
trypsin-agarose column. Trypsin-agarose was prepared by cou-
pling 20 mg of L-1-tosylamido-2-phenylethyl chloromethyl
ketone-treated trypsin (Worthington Biochemicals) to 2.5 ml
of Affi-Gel 10 in 100 mMMOPS, pH 7.4, 10 mM CaCl2, and 100
g/ml leupeptin overnight at 4 °C. This was followed by block-
ing non-reacted sites with 1 M ethanolamine-HCl, pH 8.0.
Refolded TFPI-K1 was loaded onto the prepared trypsin-agar-
ose column in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl. The
column was extensively washed with the same buffer before
eluting the inhibitor with 10 mM HCl, pH 2.1, 100 mM NaCl.
The pH of the eluted fractions was immediately neutralized
with 0.02 volumes of 2 M Tris buffer. All inhibitors were judged
95% pure by SDS-PAGE.
Recombinant human wild-type fIX and fIXK98A were iso-
lated from 293 cell supernatants using a combination of ion-
exchange and heparin affinity chromatography. A 10-fold con-
centrate of cell supernatant was diluted 2-fold with deionized
water to reduce the ionic strength before loading a 150-ml
DEAE FF Sepharose (Amersham Biosciences) column equili-
brated in 25mM sodium citrate, pH 6.0, 33 mMNaCl, and 1mM
benzamidine. After loading, the column was extensively
washed in the same buffer before elution of the fIX protein with
a 0.033–0.4 M NaCl gradient over 10 column volumes. The fIX
protein peak was identified by clotting activity, pooled, and dia-
lyzed versus 50mMTris-HCl, pH 7.5, 100mMNaCl before hep-
arin affinity chromatography using either POROS HE2
(Applied Biosystems) or HiPrepTM Heparin FF 16/10 (Amer-
sham Biosciences) and eluting with a NaCl gradient. Wild-type
fIX and fIXK98A both eluted as single peaks at roughly 0.46 M
NaCl.
Wild-type and mutant fIX proteins were activated with the
purified factor X activator from the venom of Russell’s viper,
which also cleaves fIX after Arg180 to generate active enzyme
(fIXa). The activated enzyme was purified away from the
venom protease by subsequent heparin affinity chromatogra-
phy essentially as described above usingHiTrapTMHeparinHP
(Amersham Biosciences). Although the activation peptide
remains attached to the light chain of fIXa, this enzyme
retains 100% amidolytic activity compared with fIXa (activa-
tion peptide proteolytically removed) and is comparable with
fIXa in kinetics of inhibition by Kunitz-type inhibitors (see
“Results”). Unless indicated otherwise, the fIXa formwas used
in experiments.
Clotting Assays—Coagulant activities of wild-type and
mutant fIXa proteins were assayed by a standard single-stage
clotting assay using a Coag-a-mate XM (Organon Teknika)
coagulometer, fIX-deficient plasma (George King Biomedical),
and APTT Reagent (Sigma).
Reactive Site Titration of Inhibitors—The active concentra-
tion of inhibitor preparations was determined by reactive site
titration essentially as described (23) using 10 nM active
site-titrated trypsin (30) and S-2222 substrate (Chromoge-
nix, Milano, Italy) to measure residual trypsin activity after a
15-min incubation period. This method assumes a 1:1 stoi-
chiometry of inhibitor and trypsin. Amino acid analysis per-
formed on an initial PN2-KPI preparation indicated an
equivalent concentration as that determined by reactive site
titration (not shown).
Active Site Titration of fIXa Enzymes—Active concentrations
of wild-type andmutant fIXa preparations were determined by
active site titration using biotin-EGR-ck (Hematologic Tech-
nologies Inc.) essentially as described (31). Briefly, wild-type or
mutant fIXa (roughly 5M)were incubatedwith 150Mbiotin-
EGR-ck in 50 mM Tricine, pH 8.0, 200 mM NaCl, 10 mM CaCl2,
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and 30% ethylene glycol for 24 h at room temperature. Biotin-
EGR-fIXa was then quantified by enzyme-linked immunosor-
bent assay using a goat anti-fIX polyclonal capture antibody
and alkaline phosphatase-conjugated streptavidin. These were
compared with a standard line made using native fIXa to
determine active concentrations for all fIXa enzyme
preparations.
Equilibrium Enzyme Inhibition Assays—Reversible compet-
itive inhibition of fIXa amidolytic activity at equilibrium was
measured at 25 °C using final concentrations of 25 nM fIXa, 5
mM CaCl2 and the indicated concentrations of enoxaparin and
inhibitor in the presence of 30% ethylene glycol as previously
described (15). The addition of ethylene glycol enhances the
enzymatic activity of fIXa toward CBS 31.39 roughly 20-fold
(32). Previous studies by us as well as control experiments per-
formedwith each inhibitor examined showed that the inclusion
of ethylene glycol in the assay has no effect on the reactivity of
fIXa with these inhibitors (15). Values of the final equilibrium
inhibition constant (Ki,eq) were estimated as described (15, 29)
using Equation 1. This equation describes simple reversible
competitive inhibitionwhere vo is the steady state rate obtained
in the absence of inhibitor, vs is the steady state rate at each
concentration of inhibitor, S is the experimental substrate con-
centration, and Km is the Michaelis constant for substrate
hydrolysis.
vs  vo
Ki, eq1 S/Km
I Ki, eq1 S/Km
(Eq. 1)
Slow-binding Enzyme Inhibition Analysis—Kinetic parame-
ters for slow-binding inhibition were obtained using Equations
2–5 as derived by others (33, 34) and are described in Schemes
Ia and Ib (Fig. 1). In both of these schemes the non-covalent
enzyme-inhibitor complex, EI, isomerizes into EI*; either after
significant formation of the EI complex (Scheme Ia) or without
significant accumulation of the EI complex (Scheme Ib). In
both cases, the overall inhibition constant describing genera-
tion of EI* is defined as Ki*, which is
equivalent to Ki,eq obtained from
equilibrium experiments (above). In
cases following Scheme Ia, the
parameterKi* can be further broken
down to obtain Ki, which describes
the establishment of the initial
“loose” EI complex, k5 and k6 (see
below).
Final reaction conditions were
the same as described above for
equilibrium studies. In these assays,
however, the fIXa was preincubated
with or without enoxaparin for 15
min at 25 °C in the reaction mixture
before the combined addition of
inhibitor and substrate at time 0.
The absorbance at 405 nmwas then
monitored for up to 30 min in a
ThermoMax microplate reader
(Molecular Devices) set at 25 °C to
monitor substrate hydrolysis using
KINEMAX software (written and kindly provided byDr. Jolyon
Jesty, SUSB, Stony Brook, NY). Data for each generated curve
were fitted with the following integrated rate equation describ-
ing slow-binding inhibition,
A  vst  vo  vs1  e
 kobst/kobs Ao (Eq. 2)
where A is the absorbance at 405 nm at any time, t. Fits of
progress curves with Equation 2 yield values for Ao (the initial
absorbance at t 0), vo (the initial rate of substrate hydrolysis),
vs (the steady-state rate of substrate hydrolysis), and kobs (the
apparent first-order rate constant for inhibition).
For analyses using Scheme Ia, values of k6 (the reverse rate
constant for EI* isomerization) were determined from progress
curves above using the following relationship.
k6 or k10 kobsvs/vo (Eq. 3)
Values of k5 and initial Ki (defined as k4/k3) were then obtained
from secondary plots of kobs versus I using the following hyper-
bolic equation.
kobs k6 k5I/I Ki1 S/Km (Eq. 4)
For analyses using Scheme Ib, values of k10 were obtained from
progress curves also using Equation 3. However, in these cases vo
does not varywith inhibitor concentration and aplot of kobs versus
I yields a straight line, indicating conditions where Ki (1 S/Km)
 I. Thus for Scheme Ib EI formation is insignificant and EI* can
be considered formed directly from E  I. For these cases the
following linear equation is applicable for obtaining an estimate of
k9, the apparent second-order on-rate constant,
kobs k10 k9I/1 S/Km (Eq. 5)
where the y intercept reflects k10 and the slope of the line is
equal to k9/(1  S/Km). Alternatively, k9 can be obtained from
Ki*, which is equivalent to Ki,eq in Equation 1, using the rela-
tionship k9 k10/Ki*.
FIGURE1.Reversible slow-bindingenzyme inhibition schemes. Schemes Ia and Ibbothdescribe the revers-
ible slow-binding inhibition of an enzyme (E ) by an inhibitor (I) resulting in competitive inhibition of substrate
(S) binding and the subsequent reduction in product (P) formation (33, 34). Both schemes show the formation
of theMichaelis complex (ES) as described classically by k1, k2, and k7. In Scheme Ia inhibition of enzyme occurs
in two distinct steps: 1) formation of a loose EI inhibitory complex described by k3 and k4, where k4/k3 Ki. 2)
Isomerization of EI to EI* described by k5 and k6. In Scheme Ib the binding of inhibitor and isomerization of the
complex are simultaneous andnot distinguishable. In this case k9 and k10 represent the overall on- and off-rate
constants. This situation can arisewhen k4 and k3 are very slow (rate-limiting) comparedwith k5 and k6. In both
schemes the overall inhibition is describedby Ki*, which is the final inhibition constant observed at equilibrium
of the system.
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Although fits with Equations 4 or 5 yield estimates of k6 or
k10, respectively, the values reported hereinwere obtained from
Equation 3 using the more accurate fits of progress curves to
Equation 2 and then verified in fits with Equations 4 or 5. Exper-
imental values of S as well as experimentally determined values
of Km (defined in the traditional manner as (k2  k7)/k1 in
Schemes Ia and Ib) were used as necessary in all fitting proce-
dures. All regression procedures were performed using Slide-
WritePlus 6.0 (Advanced Graphics Software), which uses the
Levenberg-Marquardt algorithm.
RESULTS
Previous studies (15) by us have shown that whereas fIXa is
resistant to inhibition by the Kunitz-type inhibitor BPTI, this
resistance is somewhat alleviated by enoxaparin, leading to a
roughly 10-fold enhancement in the equilibrium inhibition
constant. To gain further insight intomechanisms of fIXa selec-
tivity and its modulation by heparin we undertook an examina-
tion of the reactivity of fIXa with several isolated Kunitz-type
inhibitor domains: BPTI, PN2-KPI, TFPI-K1, and TFPI-K2.
Each of these inhibitors was expressed in E. coli using standard
recombinant techniques, purified to homogeneity and quanti-
fied by reactive site titration as described under “Experimental
Procedures.” The isolated PN2-KPI inhibitor domain was
found to react with high affinity toward factor XIa, yielding a
Ki,eq of roughly 400 pM (see supplemental data). Similarly, pre-
liminary studies indicated that preparations of isolated
TFPI-K1 domain inhibited the complex of factor VIIa and sol-
uble tissue factor with high affinity (Ki,eq 400 nM) and weakly
inhibited factor Xa (Ki,eq  1.5 M). Conversely, the isolated
TFPI-K2 domain inhibited factor Xa with high affinity (Ki,eq
24 nM) and the factor VIIa-tissue factor complex with reduced
affinity (Ki,eq  7 M). These results are consistent with the
expected reactivity of the isolated inhibitor domains (35, 36)
and demonstrate the correct folding and inhibitor activity of
the inhibitors examined.
The abilities of these isolated Kunitz inhibitor domains to
inhibit fIXa are compared in Fig. 2. As expected, fIXa exhib-
ited remarkable specificity toward these inhibitors despite their
high homology. Of the inhibitors examined, PN2-KPI showed
the highest level of reactivity (Ki,eq  10 M), followed by
TFPI-K2 (Ki,eq 336M), BPTI (Ki,eq 500M), and TFPI-K1
(Ki,eq  1 mM). Consistent with our previous observations,
enoxaparinwas able to enhance the reactivity of fIXawith BPTI
more than 10-fold (Ki,eq  46 M). Surprisingly, however, this
same level of enhancement by enoxaparin was not observed
with any of the other inhibitors examined; TFPI-K2 and PN2-
KPI each showed only a small, but consistent, enhancement in
reactivity with enoxaparin (1.7- and 1.4-fold, respectively; Ki,eq
values of 203 and 7 M) and TFPI-K1 showed no measurable
enhancement in reactivity with enoxaparin.
The highly basic nature of BPTI compared with the other
isolated Kunitz domains alongwith its ability to bind to heparin
(albeit weakly;Kd 172M (15)) raised the potential that enox-
aparin, although short (15 saccharide units; H15), may retain
some capacity to facilitate the interaction of BPTI with fIXa via
a bridging-type mechanism. Although unlikely based on previ-
ous equilibrium kinetic studies and the level of enoxaparin used
in these experiments (10 M; or 0.06  Kd for BPTI binding
versus 78  Kd for fIXa binding), this issue was examined by
using increasing concentrations of enoxaparin as well as pro-
gressively smaller heparin oligosaccharides; H18, H14, H10,
and H6 (18–20). As shown in Fig. 3, the typical bell-shaped
profile for bridging-type mechanisms was not observed at
enoxaparin concentrations ranging from 1 nM to 100 M. In
addition, and of greater significance, is the observation that
progressively smaller oligosaccharides do not lose the ability to
enhance reactivity of fIXa. These results along with previous
FIGURE 2. Inhibition of fIXa by isolated Kunitz-type inhibitor domains.
FIXa (25 nM) was titrated with the indicated concentrations of BPTI (E),
TFPI-K1 (F), TFPI-K2 (), andPN2-KPI (f). The remaining fIXa amidolytic activ-
ity at equilibrium was then measured and values were normalized to the
activity of fIXa in the absence of inhibitor (100%). Data were fitted with Equa-
tion 1 (lines) to obtain values of Ki,eq (see text).
FIGURE 3. Support of BPTI inhibition of fIXa by short chain oligosaccha-
rides.Theability of heparinoligosaccharideswithprogressively shorter chain
lengths to support enhancement of fIXa reactivity with BPTI was examined
using 25 nM fIXa, 308M BPTI, and the indicated concentrations of heparin-
derived oligosaccharides (18–20) from 0.01 to 200 M. Saccharide chain
lengths were H18 (F), H14 (), H10 (f), and H6 (ƒ). Enoxaparin (H15) is
shown for comparison (E). The fIXa activities were normalized to the activity
of fIXa in the absence of added oligosaccharide.
Modulation of the fIXa 99-Loop by Heparin
AUGUST 11, 2006•VOLUME 281•NUMBER 32 JOURNAL OF BIOLOGICAL CHEMISTRY 23069
kinetic studies support the ability of heparin to modulate fIXa
reactivity via amechanism other than bridging, and are consist-
ent with allosteric modulation of the fIXa protease domain.
To gain further insight into the potential mechanism of hep-
arin modulation of fIXa, we prepared a rudimentary hypothet-
ical model of the fIXa-BPTI complex using available crystal
structures of BPTI (37), fIXa (38), and the fVIIa-BPTI5L15 com-
plex (39). Using the latter structure as a template, superimpo-
sition of the native BPTI structure over the mutant BPTI struc-
ture along with superimposition of the fIXa structure over the
fVIIa structure (Discovery Studio v 1.1; Accelrys Inc.) suggested
a constriction of the fIXa active site in a manner that may be
expected not to readily accommodate BPTI. The main site of
steric hindrance seemed to be with the 99-loop of fIXa, specif-
ically residue Lys98 (Fig. 4).Wehypothesized that heparin bind-
ing may act to allosterically modulate the 99-loop of fIXa.
Based on this hypothesis, we examined a mutant of fIXa in
which Lys98 was mutated to Ala (fIXK98A). Wild-type and
mutant forms of fIXa were expressed in human 293 cells and
purified to 95% homogeneity as judged by SDS-PAGE (Fig.
5A). The fIXK98A mutant was found to retain 100% clotting
activity compared with wild-type fIXa (Fig. 5B) and upon acti-
vation retained near normal amidolytic activity toward CBS
31.39 substrate (Table 1).
We first examined the kinetics of inhibition of WT fIXa by
BPTI using the slow-binding inhibition model (33, 34). In this
model (Fig. 1, Scheme Ia) BPTI forms an initial loose inhibi-
tory complex with fIXa (defined by Ki and the rate constants
k3 and k4) followed by the slow isomerization of the EI com-
plex to EI* (defined by the rate constants k5 and k6). This
results in overall inhibition of the enzyme as defined by Ki*,
which is equivalent to the Ki,eq value determined in equilib-
rium experiments. The progress curves obtained for BPTI
inhibition of WT fIXa in the absence and presence of a sat-
urating level of enoxaparin are shown in Fig. 6, A and B,
respectively. The shapes of the progress curves support the
slow binding nature of BPTI with recombinant WT fIXa.
These curves were identical to control reactions performed
with fIXa (not shown) and are well described by Equation 2.
Values of k6 subsequently obtained using Equation 3 showed
no significant differences in the absence or presence of enox-
aparin; k6  2.7 (1.5)  103 s1 without enoxaparin and
1.2 (0.2)  103 s1 with enoxaparin.
As an independent verification of k6 an experiment was
performed where 5M fIXa was incubated with 231 M BPTI
in the presence of enoxaparin for 20 min, followed by a rapid
1,000-fold dilution into the same buffer also containing
enoxaparin. Timed aliquots of this diluted mixture were
removed into 1 mM CBS 31.39 substrate to monitor the
recovery of enzyme activity over time (Fig. 6B, inset). Under
these conditions, the BPTI concentration is over 200-fold
lower than the apparent Ki,eq and thus k6 can be approxi-
mated by the rate constant describing recovery of activity
(33, 34). Fitting the data with a single exponential equation
yielded a value for this rate constant that reasonably sup-
ports the value of k6 obtained above (1.9  103 s1).
From fits of the progress curves in Fig. 6,A and B, with Equa-
tion 2, secondary plots of kobs versus BPTI for WT fIXa show
little or no curvature (Fig. 6C). This suggests a very high initial
Ki value and an indeterminate value for k5. These observations
as well as the lack of change in vo with increasing inhibitor
FIGURE4.Hypotheticalmodelof the inhibited fIXa-BPTI complex.Ahypo-
thetical fIXa-BPTI complex model was constructed using Discovery Studio
software (Accelrys) basedonknowncrystal structuresof fIXa (PDBcode1RFN)
and fVIIa-BPTI5L15 (PDB code 1FAK) using molecular replacement. The struc-
ture revealedpotential steric hindrancebetweenBPTI and the99-loopof fIXa,
specifically Lys98 (central ball and stick structure with van der Waals radii).
BPTI is depicted in orange; fIXa is depicted in green with the 99-loop in blue;
the heparin binding exosite residues in fIXa (14) are depicted as violet sticks;
and the fIXa active site triad residues (Ser195, His57, andAsp102) aredepictedas
red sticks.
FIGURE5.A, SDS-PAGEanalysis of recombinantWT fIX and fIXK98A. Fivegof
purified WT fIX (lane 1) and fIXK98A (lane 2) were loaded onto a 12% polyac-
rylamide gel under reducing conditions for SDS-PAGE. The resulting gel was
stained with Coomassie Brilliant Blue G-250. Molecular weight markers are
indicated on the left. B, clotting activity of fIXK98A versus WT fIX. Standard
single-stage clotting assays were performed on recombinant WT fIX (E) and
fIXK98A (F), which showed equivalent coagulant activity.
TABLE 1
Kinetic parameters for CBS 31.39 hydrolysis by WT fIXa versus
fIXaK98A
Obtained by fitting the data with the Michaelis-Menton equation. Values shown
are S.E., n 6.
Enzyme Km kcat kcat/Km
M s1 M1 s1
WT fIXa 3.78 (0.08) 103 16.5 (0.69) 4.37 (0.08) 103
fIXaK98A 1.58 (0.02) 103 6.23 (0.43) 3.98 (0.27) 103
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concentrations (cf. Fig. 6, A and B)
are diagnostic for Scheme Ib. The
data of Fig. 6C were thus fitted with
Equation 5 to obtain estimates for
the apparent second-order rate con-
stant; k9  5.4 M1 s1 without
enoxaparin and 23 M1 s1 with
enoxaparin. The value obtained
above for k6 (k10 in Scheme Ib) is
consistent with the values obtained
for k10 using Equation 5; k10 1.3
103 s1 without enoxaparin and
1.2 103 s1 with enoxaparin.
A similar slow-binding kinetic
analysis was performed with WT
fIXa and PN2-KPI. In contrast to
what was observed with BPTI, sec-
ondary plots of kobs versus PN2-KPI
were hyperbolic (not shown) and
well described by Scheme Ia, yield-
ing the values of Ki, k5, and k6 given
in Table 2. The role of Lys98 and the
99-loop of fIXa in inhibition of fIXa
by both BPTI and PN2-KPI were
next examined using fIXaK98A.
This mutant fIXa showed increased
reactivity toward all of the inhibi-
tors examined (Table 3). More
importantly, the enhancing effect of
enoxaparin was substantially re-
duced when compared with WT
fIXa. Detailed analysis of the slow-
binding kinetics of inhibition of
fIXaK98A by BPTI revealed that the
major difference compared with
WT fIXa was the enhanced forma-
tion of the initial enzyme-inhibitor
complex, as seen visually by the var-
iation in initial rate (vo) of progress
curves (Fig. 7, A and B) and the
hyperbolic nature of secondary
plots (Fig. 7C). Although enoxapa-
rin significantly enhanced the reac-
tivity of both WT fIXa and
fIXaK98A toward BPTI (Table 2),
the effect on the mutant was much
reduced and was completely abro-
gated for its inhibition by PN2-KPI.
DISCUSSION
Previous studies by us have dem-
onstrated that heparin binding to
fIXa enhances fIXa reactivity with
BPTI (15). Whereas in that study
unfractionated heparin was found
to have a slightly greater effect,
enoxaparin retained most of the
ability to enhance fIXa reactivity.
FIGURE 6. Slow-binding inhibition of WT fIXa by BPTI. A, progress curves of WT fIXa inhibition by BPTI in
the absence of enoxaparin. B, progress curves of WT fIXa inhibition by BPTI in the presence of 10 M
enoxaparin. BPTI concentrations used were: 0 (E), 15.4 (F), 30.8 (), 46.2 (f), 77 (‚), 154 (Œ), 231 (ƒ), and
308 M (). Inset, recovery of enzymatic activity of WT fIXa after inhibition with BPTI and enoxaparin. The
inhibited fIXa-BPTI complex was diluted 1,000-fold and timed aliquots were removed into CBS 31.39
substrate to measure recovery of enzymatic activity over time. The activities were compared with a
parallel reaction done in the absence of inhibitor to normalize values to 100%. The data were fitted with
a single-exponential equation to determine a value for k (roughly equivalent to k10, see text). C, secondary
plots of kobs from panels A and B versus BPTI concentration for WT fIXa in the absence (F) and presence (E)
of enoxaparin. Data were fitted with Equation 5 (solid lines). Kinetic constants obtained are given in Table
2. Refitting of the data using Equation 4 as described under “Discussion” is also shown (dashed lines).
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The conclusion that heparin can modulate the active site of
fIXa is supported in the present study by several observations,
not the least of which is the ability of short chain oligosaccha-
rides to retain the ability to enhance fIXa reactivity with BPTI.
Whereas the shortest oligosaccharide examined (H6) requires
higher concentrations than do H10–H18, the higher IC50 for
H6 is consistent with the reduced binding energy one may
expect for a small oligosaccharide whose projected length
would contact only two thirds of the heparin binding exosite:
based on available crystal structures (Protein Data Bank codes
1E0O and 1BFC) the length of a decasaccharide is expected to
be	38 Å and that of a hexasaccharide is expected to be	23 Å
at full extension. This is compared with the measured length of
the identified heparin binding site on fIXa (	35 Å) based on
mutational studies (14).
With respect to the inhibition of fIXa by BPTI, two main
conclusions may be drawn from these studies: 1) fIXa residue
Lys98 is in part responsible for protecting fIXa from inhibition
by BPTI, likely via steric hindrance. Removal of this steric
obstruction bymutation of Lys98 results in greater inhibition of
fIXa by BPTI (26-fold enhancement). 2) Heparin binding to
fIXa in part counteracts the steric protection provided by Lys98.
Mutation of Lys98 results in a reduction in the ability of heparin
to further enhance reactivity of fIXa with BPTI (roughly 2-fold
effect for fIXaK98A compared with 10-fold effect with WT
fIXa). The lack of complete abrogation of the effect of heparin
suggests that other as yet undefined factors also play a role in
BPTI inhibition of fIXa and its response to heparin. This is
likely due to the movement of more than simply Lys98 and may
or may not involve other residues in the 99-loop or even the
entire loop.
It is important to note that the reduction in the effect of
heparin with the fIXaK98A mutant is not merely due to
reduced heparin binding because fIXaK98A retained the ability
to bind to heparin-Sepharose and eluted at the same salt con-
centration as WT fIXa during purification procedures. In sup-
port of this, preliminary experiments performed by titrating
fIXaK98A with enoxaparin in the presence of 100 M BPTI
yielded results consistent with the high nanomolar affinity for
enoxaparin previously observed with fIXa (Kd 128 nM (15)).
No further increase in inhibition of fIXaK98A by BPTI was
observed when the enoxaparin level was increased from 1 to 10
M (not shown). Because all experiments were conducted using
10 M enoxaparin, it seems reasonable to assume that
fIXaK98A was saturated in these experiments.
Whereas the data for fIXawith BPTI in Fig. 6C are consistent
with Scheme Ib, this scheme is essentially a simplified version of
Scheme Ia with a very large value forKi (33, 34). Examination of
the Scheme Ia kinetic constants in Table 3 for fIXa with PN2-
KPI as well as those for fIXaK98A with both inhibitors shows
fairly consistent values for k5 and k6. This suggests that once
formed, isomerization of the EI complex to EI* is essentially the
same for any of the enzyme-inhibitor pairs examined. Based on
this it seems reasonable to tentatively extend the value of k5 to
theWT fIXa-BPTI pair and re-examine the data of Fig. 6Cwith
respect to Scheme Ia. This results in fits to Equation 4 shown
in Fig. 6C as dashed lines and yields initial Ki values of 2.1 
103 M and 4.1  104 M in the absence and presence of
enoxaparin, respectively. This 5-fold difference in Ki along
with 	2-fold difference in k6 (k10) for this enzyme-inhibitor
pair (Table 2) would seem to account for the	10-fold effect
of enoxaparin observed in Ki,eq (Table 3). Unfortunately, the
rather large errors in the values of k6 (k10) preclude definitive
conclusions concerning potential effects of enoxaparin on
this rate constant.
Regardless, these results are consistent with a very weak ini-
tial interaction of fIXa with BPTI. Enoxaparin binding to the
heparin binding exosite in fIXa at least in part acts to alloster-
ically modulate the 99-loop of fIXa in a manner that facilitates
this initial interaction. The results with BPTI are in contrast to
TABLE 2
Kinetic constants for inhibition of fIXa and fIXaK98A by BPTI and PN2-KPI
Unless indicated otherwise, values of kinetic constants were obtained using Equations 3 and 4 (see text).
Enzyme Inhibitor Enoxaparin Ki k5 k9 k6 or k10a Ki*calcb
M s1 M1 s1 s1 M
WT fIXa BPTI  2.1 103 c 5.4 2.67 (1.50) 103
 4.1 104 c 23 1.17 (0.17) 103
PN2-KPI  2.0 105 1.3 102 3.67 (2.66) 103 4.4 106
 3.3 105 1.3 102 3.50 (0.67) 103 7.0 106
fIXaK98A BPTI  1.3 104 1.5 102 2.33 (0.67) 103 1.7 105
 8.8 105 1.6 102 1.65 (0.33) 103 8.2 106
PN2-KPI  6.8 106 1.4 102 2.33 (1.00) 103 9.7 107
 8.0 106 1.4 102 2.00 (0.83) 103 1.0 106
a Values are k10 for WT fIXa with BPTI (Scheme Ib) and k6 for others (Scheme Ia) S.D. (n 7).
b Calculated from k5, k6, and Ki using the relationship Ki* k6Ki/(k5 k6) (33, 34).
c Determined from refits of the data in Fig. 6C with Equation 4 using k5 obtained for fIXaK98A and BPTI (see “Discussion”).
TABLE 3
Equilibrium inhibition constants for Kunitz-type inhibitors andWT fIXa versus fIXaK98A
Enzyme Enoxaparin Ki,eqBPTI TFPI-K1 TFPI-K2 PN2-KPI
M
WT fIXa  6.46 (0.83) 104 1.0 103 4.14 (0.51) 104 9.52 (1.0) 106
 5.91 (0.32) 105 1.0 103 2.57 (0.71) 104 6.84 (0.76) 106
fIXaK98A  2.48 (0.54) 105 1.31 (0.23) 104 4.36 (0.51) 105 1.31 (0.17) 106
 1.32 (0.24) 105 1.11 (0.42) 104 2.83 (0.11) 105 1.19 (0.19) 106
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the interaction of fIXa with TFPI-K1, TFPI-K2, or PN2-KPI.
The former shows no effect of heparin binding, whereas the
latter twoshowonly small (but reproducible) responses toheparin
binding. These results would suggest that these three Kunitz
inhibitor domains are not as greatly hindered as BPTI by the
99-loopof fIXa. Indeed,mutationofLys98 enhanced the inhibition
by TFPI-K1 roughly 8-fold, TFPI-K2 roughly 9-fold, and by PN2-
KPIonly 6–7-fold. Interestingly, however, the effect of enoxaparin
on fIXaK98A reactivity toward both TFPI-K1 and TFPI-K2 was
unchanged, whereas that for PN2-KPI was completely abrogated.
Thus, there is some disparity in the role of Lys98 and additional
effects of heparin binding are likely.
Previous studies have demonstrated the ability of full-length
TFPI to inhibit fIXa with an affinity of roughly 300 nM (40). It is
thus interesting that neither the isolated TFPI-K1 nor isolated
TFPI-K2 domains retain very high reactivity with fIXa. Prelim-
inary studies indicated that our preparations of isolated inhib-
itor domainswere of good quality and activity. Thiswould seem
to indicate that the folding and activity of these inhibitor
domains are correct. Taken as a whole, the results here would
seem to imply that either the connecting regions of TFPI are
important for its activity toward fIXa or other structural/topo-
logical elements are involved. Nonetheless, it is likely that the
TFPI-K2 domain is the inhibitor domain of TFPI most likely
responsible for interaction with fIXa. Although the isolated
third Kunitz repeat of TFPI was not examined in this study, this
domain is likely not an active inhibitor domain per se (41).
The ability ofheparin toallostericallymodulate theactive siteof
fIXa demonstrates the ability of fIXa to respond to binding at this
exosite. This observation ismademore interesting by the observa-
tion by Sheehan et al. (42, 43) that the heparin binding exosite in
part represents a fVIIIa interactive site on fIXa. Thus, whereas
heparin binding in itself may inhibit fIXa coagulant activity via
steric hindrance of fVIIIa binding, fVIIIa binding to this exosite
may inversely act to allostericallymodulate fIXa in an as yet unde-
finedmanner. Although previous studies found no effect of fVIIIa
on fIXa inhibition by the isolated PN2-KPI domain (44), this is
consistentwith our observations here using enoxaparin in place of
fVIIIa and does not preclude potential effects of fVIIIa toward
other inhibitors. It thus remains possible that occupation of this
exosite by fVIIIa, like heparin, results in inhibitor-specific modu-
latory effects. Alternatively, the modulating effect of heparin on
the 99-loop may be simply due to heparin-specific electrostatic
forces that are introducedbyheparinbinding in closeproximity to
Lys98 (cf. Fig. 4). These forces may or may not be mimicked by
fVIIIa binding. Further clarification of these issues must await
future studies.
The allostericmodulation of fIXa by enoxaparin is somewhat
reminiscent of the effect of thrombomodulin on the interaction
of thrombin with BPTI, where binding of thrombomodulin
alters the conformation of one of the specificity loops (60-loop)
at the mouth of the active site of thrombin, resulting in
enhanced reactivity with BPTI (45). Interestingly, in that study
the chondroitin sulfate moiety of thrombomodulin (which
binds to the heparin binding site on thrombin; anion binding
exosite 2) further enhanced the inhibition of an E192Qmutant
of thrombin but not wild-type thrombin. Comparison of the
sequence of fIXawith thrombin reveals that fIXa contains aGln
at position 192, similar to the thrombin E192Qmutant and fXa.
In addition, previous studies have revealed that mutation of the
homologous residue in fVIIa (Lys192) to Gln enhances its reac-
tivity with BPTI (29), and that mutation of Gln192 in fIXa
altered its reactivity toward TFPI (40). Neither of these studies
examined the potential effect of heparin on reactivitywith these
Kunitz inhibitors. These studies are intriguing and seem to
implicate residue 192 in potential heparin responsiveness along
with the 99-loop. The investigation of potential interplay
between residue 192 and the 99-loop of fIXa in its response to
heparin binding is beyond the scope of the present study, how-
ever, and must await future studies.
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FIGURE 7. Slow-binding inhibition of fIXaK98A by BPTI. A, progress curves
of fIXaK98A inhibition by BPTI in the absence of enoxaparin. B, progress
curves of fIXaK98A inhibition by BPTI in the presence of 10 M enoxaparin.
BPTI concentrations used were: 0 (E), 15.4 (F), 30.8 (), 46.2 (f), 77 (‚), 154
(Œ), and 231M (ƒ). C, secondary plots of kobs from panels A and B versus BPTI
concentration for fIXaK98A in the absence (F) and presence (E) of enoxapa-
rin. Data were fitted with Equation 4 (lines). Kinetic constants obtained are
given in Table 2.
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Table S1.  Amino Acid Sequence Alignment of Kunitz-type inhibitor domains* 
  1 10 20 30 40 50  
"'''''''''''''''''''''''''''''''X
BPTI   RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA
PN2-KPI EVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSA
TFPI-K1   MHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRD
TFPI-K2   KPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDG
TFPI-K3   GPSWCLTPADRGLCRANENRFYYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKK 
*Conserved amino acids with BPTI are shaded. Reactive site loops (thin boxes) and stabilizing loops
(thick boxes) are held in close proximity by a disulfide bond between Cys14 and Cys38 (indicated). The P1 
reactive site residues are in bold.
 
 
 
 
 
 
 
 
 
Figure S1. SDS-PAGE analysis of isolated 
Kunitz inhibitor domains. Approximately 
5–10 :g of each purified inhibitor was 
loaded onto a 12% polyacrylamide gel for 
electrophoresis. Lane 1 – BPTI; lane 2 – 
PN2-KPI; lane 3 – TFPI-K1; and lane 4 – 
TFPI-K2. The gels were each stained with 
Coomassie Brilliant Blue. Molecular 
weight markers are indicated on the left. 
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Figure S2. Quality and activity check of PN2-KPI. Factor XIa 
(1 nM; Haematologic Technologies, Inc.) was incubated at 
room temperature for 15 min with the indicated concentrations 
of reactive-site titrated PN2-KPI in 50 mM Tris-HCl pH 7.5, 
100 mM NaCl and 0.1 % BSA. The chromogenic substrate S-
2366 (Chromogenix) was added to 1 mM and the initial rate of 
amidolytic activity was recorded at 405 nm.  Reaction rates 
obtained (mOD/min) were converted to percentage activity 
and plotted as a function of inhibitor concentration. The data 
were fit with an equation describing tight-binding inhibition 
where IC50 = Ki (1+S/Km) + 0.5[E] (34) to yield a Kieq of 
roughly 400 pM using a value of Km=0.4 mM.  
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Figure S3. Quality and activity check of TFPI-K1 and TFPI-K2. A. Inhibition of the complex 
of factor VIIa and soluble  tissue factor. The indicated concentrations of TFPI-K1 (M) or 
TFPI-K2 (F) were incubated with 5 nM factor VIIa (Haematologic Technologies, Inc.) , 100 
nM recombinant soluble tissue factor (16) and 5 mM Ca2+ in 20 mM Hepes-NaOH pH 7.4, 
100 mM NaCl and 0.1% BSA for 15 minutes at room temperature as previously described 
(24). The chromogenic substrate Chromozym-tPA (Roche Diagnostics) was then added to 1 
mM and the initial rate of amidolytic activity was monitored at 405 nm. Reaction rates 
obtained (mOD/min) were converted to percentage activity and plotted as a function of 
inhibitor concentration. Fits of the data with Equation 1 yielded Kieq values of 400 nM for 
TFPI-K1 and ~7 :M for TFPI-K2. B. Inhibition of factor Xa. The indicated concentrations of 
TFPI-K1 (M) or TFPI-K2 (F) were incubated with 5 nM factor Xa and 5 mM Ca2+ in 20 mM 
Hepes-NaOH pH 7.4, 100 mM NaCl and 0.1% BSA for 15 minutes at room temperature. The 
chromogenic substrate S-2222 (Chromogenix) was then added to 0.5 mM and the initial rate 
of amidolytic activity was monitored at 405 nm. Reaction rates (mOD/min) were converted to 
percentage activity and plotted as a function of inhibitor concentration. Fits of the data with 
Equation 1 yielded Kieq values of >1.5 :M for TFPI-K1 and 24 nM for TFPI-K2. 
